Inner-city availability of preservative-containing albuterol

Clinical Pediatrics

Volumn 43, Issue 7, 2004, Pages 615-617

  Reznik, Marina ^a   Sharif, Iman ^a   Ozuah, Philip O ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZALKONIUM CHLORIDE; PRESERVATIVE; SALBUTAMOL;

ARTICLE; NEBULIZATION; PHARMACY; PRESCRIPTION; TELEPHONE; UNITED STATES;

ALBUTEROL; BENZALKONIUM COMPOUNDS; BRONCHODILATOR AGENTS; CROSS-SECTIONAL STUDIES; DRUG COMBINATIONS; NEW YORK CITY; PHARMACIES;

EID: 4544238894     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/000992280404300705     Document Type: Article

References (16)

1. Delgado A, Chou KJ, Silver EJ, et al. Nebulizers vs metered-dose inhalers with spacers for bronchodilator therapy to treat wheezing in children aged 2 to 24 months in a pediatric emergency department. Arch Pediatr Adolesc Med. 2003;157(1):76-80.
2. Ploin D, Chapuis FR, Stamm D, et al. High-dose albuterol by metered-dose inhaler plus a spacer device versus nebulization in preschool children with recurrent wheezing: a double-blind, randomized equivalence trial. Pediatrics. 2000;106(2 Pt 1):311-317.
3. Beasley R, Fishwick D, Miles JF, et al. Preservatives in nebulizer solutions: risks without benefit. Pharmacotherapy. 1998;18(1):130-139.
4. Crain EF, Weiss KB, Bijur PE, et al. An estimate of the prevalence of asthma and wheezing among inner-city children. Pediatrics. 1994;94(3):356-362.
5. Available at: YellowPages.com.
6. Beasley CRW, Rafferty P, Holgate ST. Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebulizer solution. BMJ. 1987;294:1197-1198.
7. Zhang YG, Wright WJ, Tam WK, et al. Effects of inhaled preservatives on asthmatic subjects, II: benzalkonium chloride. Am Rev Respir Dis. 1990;141:1405-1408.
8. Miszkiel KA, Beasley R, Rafferty P, et al. The contribution of histamine release to bronchoconstriction in asthma. Br J Clin Pharmacol. 1988;25:157-163.
9. O'Callaghan CO, Milner AD, Swarbrick A. Paradoxical determination in lung function after nebulised albuterol in wheezy infants. Lancet. 1986;2:1424-1425.
10. Prendiville A, Green S, Silverman M. Paradoxical response to nebulizer albuterol in wheezy infants, assessed by partial expiratory flow-volume curves. Thorax. 1987;42:86-91.
11. Boucher M, Roy MT, Henderson J. Possible associations of benzalkonium chloride in nebulizer solutions with respiratory arrest. Ann Pharmacother. 1992;26:772-773.
12. Menendez R, Lowe R, Kersey J. Benzalkonium chloride and bronchoconstriction. J Allergy Clin Immunol. 1989;84:272-274.
13. Asmus MJ, Barros MD, Liang J, et al. Pulmonary function response to EDTA, an additive in nebulized bronchodilators. J Allergy Clin Immunol. 2001;107:68-72.
14. Kwong T, Flatt A, Crane J, Beasley R. The effect of benzalkonium chloride on the bronchodilator response to albuterol nebuliser solution. N Z Med J. 1990;103:457.
15. Department of Health and Human Services. Food and Drug Administration. 21 CFR Part 200. Sterility Requirement for Aqueous-Based Drug Products for Oral Inhalation. Federal Register. Vol. 65, No. 103; May 26, 2000.
16. Beasley R, Burgess C, Holt S. Call for worldwide withdrawal of benzalkonium chloride from nebulizer solutions. J Allergy Clin Immunol. 2001;107:222-223.